Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (July 9th Preview)
-
AI-designed peptides that predict receptor activity
University of Pennsylvania researchers and The Chinese University of Hong Kong presented TD3B, an AI framework aimed at streamlining peptide drug design. The system generates peptide candidates while also predicting their biological effect on target receptors, addressing a key gap between sequence generation and functional activity forecasting. The approach was shared as a Spotlight at the 2026 International Conference on… (per the provided item) and underscores a growing push toward “design with intent,” where candidate molecules are evaluated in silico for mechanism-relevant properties before synthesis. If validated broadly, receptor-effect prediction could shorten peptide hit-to-lead cycles and improve the quality of candidates entering early development, particularly for receptor-mediated indications where pharmacology is tightly linked to binding and downstream signaling.
-
Rheumatoid arthritis precision immunology merger and phase 2 plan
Chemolab Therapeutics and Scipher Medicine announced plans to merge and rebrand as Scipher Medicine Corporation, positioning the combined company to advance nebokitug toward a phase 2 trial in rheumatoid arthritis. The merger sets a 68%/32% split between existing Scipher and Chemomab (Chemolab) equity holders and keeps Scipher CEO Reginald Seeto at the helm. Management said the initial focus will be on nebokitug, an anti-CCL24 monoclonal antibody, after preclinical work suggested potential across immune-fibrotic disorders. A topline readout is expected in the first half of 2028, and the phase 2 trial is planned using standard FDA RA endpoints and PrismRA to guide enrollment. Scipher also highlighted its blood-based PrismRA assay, plus an AI Network Medicine platform that prioritized CCL24 and developed a proprietary response signature. The transaction is supported by approximately $30 million in commitments from current investors, with closing cash projected to fund operations through mid-to-late 2028.
-
FDA accelerated approval for first-in-class BAFF/APRIL IgA nephropathy drug
The FDA granted accelerated approval to Vera Therapeutics’ Trutakna (atacicept-vymj) for adults with primary IgA nephropathy (IgAN) at risk for progression, according to the company. Trutakna is described as the first dual BAFF and APRIL inhibitor in the indication and is delivered once weekly via an auto-injector. In a prespecified interim analysis from the ongoing ORIGIN 3 trial, Trutakna achieved a 46% reduction from baseline in proteinuria, with a 42% clinically meaningful reduction versus placebo at 36 weeks (p<0.0001). The most common adverse reactions were infections and local administration reactions. Vera framed the approval as a milestone for an immunological driver of IgAN where current therapies can fail to prevent disease progression. The company also indicated a confirmatory path is underway to support longer-term outcomes beyond proteinuria reduction.
-
Heart disease trial failure deepens competitive pressure in ATTR cardiomyopathy
AstraZeneca said its heart disease drug Wainua, developed with Ionis Pharmaceuticals, failed to outperform placebo in a pivotal trial in transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM). The result missed endpoints tied to cardiovascular death and clinical events. The setback increases pressure on AstraZeneca’s cardiovascular pipeline and shifts competitive expectations for RNA-targeting and other therapies in ATTR-CM. Provided coverage also notes immediate market reaction, with shares down in premarket trading. For the field, the failure reinforces how difficult it remains to demonstrate incremental clinical benefit in ATTR-CM, even as biologic and antisense approaches aim to slow disease progression.
-
Megadeal reshapes rare endocrinology portfolio with Crinetics
Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for about $10 billion in cash, marking the largest deal in Vertex’s history and expanding the company beyond cystic fibrosis. Vertex will add Palsonify (paltusotine), an approved once-daily oral SST2 agonist for acromegaly, plus atumelnant, an oral ACTH receptor antagonist in phase 3 for congenital adrenal hyperplasia (CAH). The transaction is expected to close in the third quarter of 2026 and includes bridge financing of $4.5 billion committed by Bank of America and Morgan Stanley. Crinetics’ portfolio adds endocrinology as a new commercial pillar for Vertex, alongside its existing specialties. Vertex estimates peak combined sales potential of more than $5 billion for Palsonify and atumelnant, and both boards approved the acquisition unanimously.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.